Electromed's Q4 revenue slightly beats estimates on homecare strength

Electromed

25/08/2026 21:15

Overview
US airway clearance device maker's fiscal Q4 revenue rose, slightly beating analyst expectations
Fiscal Q4 net income rose 54%, beating analyst estimates
Company repurchased $3.9 mln of its common stock in fiscal 2026

Outlook
Electromed did not provide specific financial guidance for the upcoming quarter or fiscal year in press release

Result Drivers
HOMECARE SALES GROWTH - Co said Q4 revenue growth was primarily driven by increased direct sales representatives, higher sales rep productivity, and improved net revenue per approval
HIGHER GROSS MARGIN - Co attributed Q4 gross profit and margin improvement to increased revenue and higher net revenue per device
INCREASED SG&A EXPENSES - Co said higher SG&A expenses were mainly due to increased salaries and incentive compensation for more personnel in sales, sales support, marketing, and reimbursement teams

Company press release: ID:nBwPVYl0a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$19.40 mln
$19.33 mln (3 Analysts)
Q4 EPS
 
$0.39
 
Q4 Net Income
Beat
$3.40 mln
$2.73 mln (3 Analysts)
Q4 Operating Income
 
$3.80 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Electromed Inc is $40.00, about 0.7% below its August 24 closing price of $40.29
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
Aug 24 - China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitions
Aug 24 - China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growth
Aug 24 - Capricor's Duchenne drug gets three-month FDA extension after new data submission

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)